Pankti Reid, MD
Rheumatology · Chicago, ILNPI 1427491711
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 65.0% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $33,661, more than ten times the $234 reported in 2019. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $521.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$34K
- AbbVie$7K
- UCB, Inc.$6K
- Novartis$3K
- Astellas Pharma Europe Ltd$2K
- GSK$215
- plus $501 from 9 others
What the payments were for
- Consulting fees$16,81932%
- Speaking & faculty fees$27,37553%
- Travel & lodging$5,01910%
- Food & beverage$2,9076%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $33,858 |
| AbbVie | 20 | $6,658 |
| UCB, Inc. | 14 | $6,402 |
| Novartis | 3 | $2,795 |
| Astellas Pharma Europe Ltd | 1 | $1,690 |
| GSK | 6 | $215 |
| AstraZeneca | 1 | $118 |
| Boehringer Ingelheim | 1 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $92 |
| Lilly USA, LLC | 3 | $58 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Genentech USA, Inc. | 2 | $33 |
| Pfizer | 1 | $28 |
| Johnson & Johnson | 1 | $14 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,119 in reported general payments places this provider in the 90th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orencia ClickjectAbatacept | 13 | $74,418 |
| KevzaraSarilumab | 15 | $65,267 |
| Diclofenac Sodium | 13 | $3,430 |
| Mycophenolate Mofetil | 18 | $2,400 |
| Colchicine | 31 | $1,967 |
| Hydroxychloroquine Sulfate | 44 | $1,577 |
| MethotrexateMethotrexate Sodium | 46 | $1,164 |
| Prednisone | 113 | $1,130 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $151 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $143 |
| Allopurinol | 14 | $134 |
| Pantoprazole Sodium | 14 | $94 |
| Cyclobenzaprine Hcl | 11 | $76 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Chicago
- Manish JainChicago$1.9M
- Theodore PincusChicago$524K
- Eric RudermanChicago$440K
- Anisha DuaChicago$280K
- Arthur MandelinChicago$270K
- Robert WoodrickChicago$143K
- Maria SosenkoChicago$87K
- Ailda NikaChicago$74K
- Duncan MooreChicago$71K
- Timothy NiewoldChicago$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.